ArticlePLoS neglected tropical diseases2026
The hydatid cyst fluid protein EgAgB8/1 demonstrates potent immunogenicity by eliciting robust humoral and cellular immune responses in mice.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic echinococcosis (CE), a neglected zoonotic disease caused by the larval stage of Echinococcus granulosus, requires effective vaccine strategies for sustainable control. This study evaluated the immunogenic profiles of two antigenic targets: EgAgB8/1, a dominant immunogenic component of hydatid cyst fluid, and Eg-01883, a protoscolex-specific antigen identified through bioinformatic screening. METHODOLOGY/PRINCIPAL
findingsE. granulosus strains were isolated from infected dogs for genomic DNA extraction. Recombinant proteins rEgAgB8/1 and rEg-01883 were expressed in E. coli, purified, and validated by SDS-PAGE and western blot. Initial protein microarray screening identified rEgAgB8/1 as exhibiting markedly higher immunoreactivity with cystic echinococcosis (CE) patient sera compared to the minimally reactive Eg-01883. Based on this finding, subsequent investigation focused on rEgAgB8/1 using a BALB/c mouse immunization model. The recombinant protein elicited potent humoral immunity, with antigen-specific IgG titers reaching 1:16,000, and stimulated significant lymphocyte proliferation. Immunized mouse sera specifically recognized native EgAgB8/1 in hydatid crude antigen preparations, confirming natural antigenicity. Flow cytometric analysis demonstrated that rEgAgB8/1 immunization significantly expanded splenic plasmablasts, memory B cells, and T follicular helper cells. Furthermore, it enhanced IFN-γ production in both CD4⁺ and CD8 ⁺ T cells while maintaining baseline IL-10 ⁺ T cell frequencies, and induced robust T cell memory responses. Statistical analyses were performed using Student's t-test for comparative evaluation.
conclusionsThese findings establish rEgAgB8/1 as a highly immunogenic antigen capable of eliciting a cellular immune response characterized by dominant IFN-γ production without concomitant IL-10 elevation, alongside durable humoral responses in mice. The comprehensive immunogenicity profile supports further research into its immunological potential against cystic echinococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.